openPR Logo
Press release

SpectraCell Now Offers LPP Cardiovascular Testing in New York

04-27-2011 09:02 AM CET | Health & Medicine

Press release from: SpectraCell Laboratories, Inc.

Houston, TX – April 26, 2011. SpectraCell Laboratories has officially been granted a license to provide its Lipoprotein Particle Profile™ (LPP™) test, which assesses cardiovascular risk, to New York state physicians and patients. The recently patented LPP™ test has been commercially available to the other 49 states since 2006.

SpectraCell began the process of acquiring a licensure in 2008 with an application submission the state of New York. The laboratory underwent an initial inspection by the New York State Department of Health in late 2009 followed by extensive documentation validating the LPP™ procedure, which is standard protocol required of all diagnostic laboratories. A final inspection in December 2010 concluded the evidentiary process, proving the LPP™ technology is valid, accurate and reproducible.

“Acquiring our New York license allows us to serve the largest metropolitan area in the country,” states Dr. Fred Crawford, PhD, VP of Operations and Laboratory Director at SpectraCell Labs. “In fact, many physicians in the state of New York have wanted to implement the LPP™ test in their practice but were unable to do so until now. Plus, we recently streamlined our LPP™ report using feedback from existing LPP™ clients, making it easier than ever for physicians to translate LPP™ results into clinical decisions.”

New York represents a large market for laboratory testing. According to a CNN report, approximately 40,000 physicians practice within a 30 mile radius of New York City, in contrast to a national average of about 8000 physicians for other American cities.

After visiting the laboratory and reviewing the testing protocol, Dr. Robert Rej, Director of Chemistry for the State of New York Department of Health recommended the permit be approved for SpectraCell’s LPP™ testing. The license also allows SpectraCell to add FDA approved chemistry procedures to New York clients. Their first addition will be LpPLA2 testing (lipoprotein-associated phospholipase A2) which measures a specific enzyme linked to thrombosis (blood clots), indicating a higher risk of heart attack or stroke.

Just a few months ago, SpectraCell Laboratories was awarded a patent on their Lipoprotein Particle Profile™ (LPP™) test, which measures both the size and number of lipoproteins rather than the cholesterol contained within them. In recent years, more doctors have seen standard cholesterol tests label a patient “normal” when in reality their risk for heart disease is quite high.

In fact, The National Cholesterol Education Program (NCEP) acknowledges that 50% of people that have heart attacks have “normal” cholesterol – that is, cholesterol below 200 mg/dL. The LPP™ test allows physicians to stratify risk more accurately, thus prescribing therapies that will be the most effective, depending on their patients’specific lipid profile.

NCEP recognizes four risk factors that are not measured with routine cholesterol testing but are all measured by the LPP™ test:

1. RLP – (remnant lipoprotein) more easily converted into arterial plaque than other lipoproteins
2. Lp(a) – a dangerous lipoprotein that contributes to clot formation
3. HDL2b – a type of HDL that indicates how well cholesterol is being cleared from your system
4. Small, dense LDL – easily penetrates vascular wall, causing damage and plaque

The LPP™ is part of the trend toward more individualized medicine. The LPP™ test, which is done on a fasting blood sample, is usually covered by insurance. Results typically take 3-5 days. For more information, go to www.spectracell.com.

About SpectraCell Laboratories – SpectraCell is a CLIA accredited laboratory that services healthcare providers nationwide by providing advanced clinical testing such as micronutrient testing, telomere analysis, Omega 3 Index and the Lipoprotein Particle Profile™ (LPP™).

SpectraCell’s Lipoprotein Particle Profile™ is the most advanced lipoprotein test available. Unlike traditional cholesterol tests, SpectraCell’s LPP™ directly measures both the size (density) and number of several classes of lipoprotein particles providing an accurate assessment of cardiovascular risk.

SpectraCell Laboratories, Inc.
10401 Town Park Dr.
Houston, TX 77072

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release SpectraCell Now Offers LPP Cardiovascular Testing in New York here

News-ID: 172572 • Views: 1063

More Releases from SpectraCell Laboratories, Inc.

SpectraCell Announces 2012 Webinar Series
Houston, TX- January 31, 2012. SpectraCell announces the first half of its 2012 lineup of educational webinars. Although the presentation content is geared toward physicians, they are free to the public and emphasize the clinical implications of nutritional deficiencies on health and disease: SpectraCell 2012 Webinar Series: January – Telomere Testing: A New Tool for Your Age Management Practice presented by: Dr. Dian Ginsberg, MD, OB/Gyn in Houston, Clinical Director
SpectraCell Receives Patent on its LPP Cardiovascular Test
Houston, TX - February 7, 2011. SpectraCell Laboratories has recently been awarded a patent on their Lipoprotein Particle Profile™ (LPP ™) test which is used to measure cardiovascular risk. The LPP™ has been commercially available since 2006, and is a type of advanced cholesterol test that measures lipoprotein subgroups. The LPP™ gives more accurate estimation of cardiovascular risk compared to a routine cholesterol test. The patent

More Releases for LPP™

Extreme Ultraviolet Lithography (EUVL) Systems Market by Light Source (Laser Pro …
According to a new report published by Allied Market Research, titled; "Extreme Ultraviolet Lithography (EUVL) Systems Market by Type, by Light Source, Equipment, and Application: Global Opportunity Analysis and Industry Forecast, 2014-2022," the extreme ultraviolet lithography (EUVL) systems market was valued at $650 million in 2015 and is projected to reach $1,195 million by 2022, growing at a CAGR of 9.2% from 2016 to 2022. The laser-produced plasmas segment held
Automotive Pump Market: Emerging Economies Expected to Influence Growth until 20 …
Fact.MR has published a new research report titled “Automotive Pump Market: Emerging Economies Expected to Influence Growth until 2022” to its online database that tries to unveil the various scenarios prevailing in the Automotive Pump Market. This assessment delivers a smart compilation of primary and secondary data which provides a clear insight about the Future Plans Expected to Impact the Automotive Pump Market. This study comprises of prominent data which
Growth Predictions on Global Automotive Pump Market Through 2022 Presented in Ne …
Increasing inclination of automobile manufacturers towards adoption of green technologies has had a seminal impact on the dynamics of automotive pumps market. In the years to come, advancements in automotive pumping technology will have the potential to maximize the influence of automotive pumps in boosting the efficiency of automobiles. Request For Free Sample Report- https://www.factmr.com/connectus/sample?flag=S&rep_id=25 Automotive pumps convey automotive fluids in a vehicle. Common fluids pumped by automotive pumps include fuel, oil,
Automotive Pump Market : Soaring Demand Assures Motivated Revenue Share during 2 …
Increasing inclination of automobile manufacturers towards adoption of green technologies has had a seminal impact on the dynamics of automotive pumps market. In the years to come, advancements in automotive pumping technology will have the potential to maximize the influence of automotive pumps in boosting the efficiency of automobiles. Get sample copy of this report: https://www.factmr.com/connectus/sample?flag=S&rep_id=25 Automotive pumps convey automotive fluids in a vehicle. Common fluids pumped by automotive pumps include fuel,
Global Automotive Windshield Pump Market Insights, Size, Share |Key Players are …
Global Automotive Windshield Pump Market Overview: The windshield washer pump is driven by a small electric motor. It is usually found attached to the washer fluid reservoir. Depending on the type of vehicle, the location of the Automotive Windshield pump is varied. Sometimes, the washer pump is connected to the wiper motor, which is located below the windshield wipers under the cowl. These products are gaining popularity with an increase in
High Pressure Vessels Global Market 2018: Key Players – Mersen, Hexagon xperio …
High Pressure Vessels Industry Description Wiseguyreports.Com Adds “High Pressure Vessels -Market Demand, Growth, Opportunities and Analysis Of Top Key Player Forecast To 2023” To Its Research Database This report studies the High Pressure Vessels market status and outlook of global and major regions, from angles of manufacturers, regions, product types and end industries; this report analyzes the top manufacturers in global and major regions, and splits the High Pressure Vessels market by product